Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales

[1]  B. Cowie,et al.  Time for universal hepatitis B screening for Australian adults , 2021, The Medical journal of Australia.

[2]  P. Austin,et al.  Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time , 2020, Hepatology.

[3]  M. Alavi,et al.  High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. , 2020, Journal of hepatology.

[4]  S. McPhail,et al.  Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis , 2020, Internal medicine journal.

[5]  M. Hellard,et al.  Enhancing the hepatitis B care cascade in Australia: A cost‐effectiveness model , 2019, Journal of viral hepatitis.

[6]  B. Cowie,et al.  Modeling Progress Toward Elimination of Hepatitis B in Australia , 2019, Hepatology.

[7]  G. Ahlenstiel,et al.  Interferon Lambda and Liver Fibrosis. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[8]  S. Pascual,et al.  Surveillance and diagnosis of hepatocellular carcinoma: A systematic review , 2019, World journal of clinical cases.

[9]  M. Alavi,et al.  Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. , 2019, Journal of hepatology.

[10]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[11]  B. Cowie,et al.  Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030 , 2018, Journal of gastroenterology and hepatology.

[12]  B. Cowie,et al.  Cultural and linguistic diversity of people living with chronic hepatitis B in 2011–2016: changing migration, shifting epidemiology , 2018, Australian and New Zealand journal of public health.

[13]  J. Lazarus,et al.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. , 2018, Journal of hepatology.

[14]  B. Sander,et al.  Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study , 2018, PloS one.

[15]  G. Dore,et al.  Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia , 2018, Journal of viral hepatitis.

[16]  M. Alavi,et al.  Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012 , 2018, BMC Infectious Diseases.

[17]  M. Porwal,et al.  Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia , 2017, Clinical epidemiology.

[18]  M. Buti,et al.  The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B , 2017, Hepatology.

[19]  M. Alavi,et al.  Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development. , 2017, Journal of hepatology.

[20]  C. la Vecchia,et al.  Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.

[21]  M. Alavi,et al.  Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). , 2016, Journal of hepatology.

[22]  M. Alavi,et al.  Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. , 2016, Journal of hepatology.

[23]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[24]  S. Hutchinson,et al.  Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis , 2015, European journal of gastroenterology & hepatology.

[25]  R. Bataller,et al.  Trends in the management and burden of alcoholic liver disease , 2015, Journal of hepatology.

[26]  H. Chan,et al.  Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. , 2015, Journal of hepatology.

[27]  V. Wong,et al.  Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease , 2015, Nature Communications.

[28]  F. Poordad.  Presentation and complications associated with cirrhosis of the liver , 2015, Current medical research and opinion.

[29]  Lungen Lu,et al.  Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C , 2014, Journal of clinical and translational hepatology.

[30]  G. Wong,et al.  Prediction of fibrosis progression in chronic viral hepatitis , 2014, Clinical and molecular hepatology.

[31]  Lequn Li,et al.  Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma , 2014, Annals of surgery.

[32]  Amit G. Singal,et al.  Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis , 2014, PLoS medicine.

[33]  B. Cowie,et al.  The burden of chronic hepatitis B virus infection in Australia, 2011 , 2013, Australian and New Zealand journal of public health.

[34]  G. Zoli,et al.  Alcohol use in adults. , 2013, The New England journal of medicine.

[35]  K. Cheung,et al.  Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma , 2013, Alimentary pharmacology & therapeutics.

[36]  G. Dore,et al.  Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[37]  Heather Walters,et al.  Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use , 2012, BMC Health Services Research.

[38]  Sharon Whipkey.  A year from diagnosis. , 2011, Nephrology news & issues.

[39]  A. Lok,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. , 2010, Journal of hepatology.

[40]  THE WORLD HEALTH ORGANIZATION , 1954 .

[41]  M. Dickie,et al.  Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .

[42]  E. Cholongitas,et al.  The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis , 2015, Annals of gastroenterology.

[43]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[44]  K. Fushimi,et al.  American Journal of Epidemiology Practice of Epidemiology Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data from 6 Countries , 2022 .